831242-05-8

Basic information

• Product Name: L-Leucinamide, N-(2-methyl-1-oxo-2-propenyl)glycyl-L-phenylalanyl-N-[2-oxo-2-(2-thioxo -3-thiazolidinyl)ethyl]-
• CAS NO: 831242-05-8
• Molecular Formula: C26H35N5O5S2
• Molecular Weight: 561.726
• Mol File: 831242-05-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: L-Leucinamide, N-(2-methyl-1-oxo-2-propenyl)glycyl-L-phenylalanyl-N-[2-oxo-2-(2-thioxo -3-thiazolidinyl)ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Leucinamide, N-(2-methyl-1-oxo-2-propenyl)glycyl-L-phenylalanyl-N-[2-oxo-2-(2-thioxo -3-thiazolidinyl)ethyl]-(831242-05-8)
• EPA Substance Registry System: L-Leucinamide, N-(2-methyl-1-oxo-2-propenyl)glycyl-L-phenylalanyl-N-[2-oxo-2-(2-thioxo -3-thiazolidinyl)ethyl]-(831242-05-8)

Safety Data

• Hazardous Substances Data: 831242-05-8(Hazardous Substances Data)

Upstream product

• 134469-06-0 thiazolidine-2-thione 
• 104845-48-9 N-methacryloylglycylphenylalanylleucylglycine 
• 96-53-7 2-mercaptothiazoline 

Downstream Products

• 1334238-76-4 N-methacyloylglycylphenylalanylleucylglycyl-gemcitabine 

Relevant articles and documents

Polymer Cancerostatics Targeted with an Antibody Fragment Bound via a Coiled Coil Motif: In Vivo Therapeutic Efficacy against Murine BCL1 Leukemia

A BCL1 leukemia-cell-targeted polymer–drug conjugate with a narrow molecular weight distribution consisting of an N-(2-hydroxypropyl)methacrylamide copolymer carrier and the anticancer drug pirarubicin is prepared by controlled radical copolymerization fo

Polymer therapeutics with a coiled coil motif targeted against murine BCL1 leukemia

The specificity of polymer conjugates based on N-(2-hydroxypropyl) methacrylamide (HPMA) bearing cytostatic drugs for cancer cells could be significantly increased by the incorporation of a suitable targeting ligand, such as a monoclonal antibody (mAb). However, direct binding of the protein to the polymer carrier could cause considerable problems, such as decreasing the binding capacity of mAb to its target. Here, we introduce a novel strategy of joining a targeting moiety to a polymeric conjugate with cytostatic drug. The scFv of B1 mAb (specific for BCL1 leukemia cells) was tagged with peptide K ((VAALKEK)4). Peptide E ((VAALEKE)4), which forms a stable coiled coil structure heterodimer with peptide K, was assembled with the HPMA copolymers bearing doxorubicin. Such targeted polymeric conjugates possess very selective and high binding activity toward BCL1 cells. Similarly, targeted polymeric conjugates exert approximately 100 times higher cytostatic activity toward BCL1 cells in comparison to nontargeted conjugates in vitro. At the same time, the conjugates have comparable and rather low cytostatic activity for 38C13 cells, which are used as a negative control, in vitro.